TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, has announced its upcoming presentation at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting.
The event will take place from May 13-17 in New Orleans, LA, with both in-person and virtual attendance options. The company will present a poster focused on "CD45 as a Universal Target for Adjuvant TCR-T Cell Therapy Following Allogeneic Hematopoietic Cell Transplantation."
- Presentation Date: Tuesday, May 13
- Time: 6:00 - 7:30 p.m. Central Time
- Location: Poster Hall, Hall I2
- Abstract Number: AMA1180
The presentation materials will be made available on TScan's website (tscan.com) in the "Publications" section after the presentation concludes.
TScan Therapeutics (Nasdaq: TCRX), un'azienda biotecnologica in fase clinica che sviluppa terapie con cellule T ingegnerizzate con TCR per il trattamento del cancro, ha annunciato la sua prossima presentazione al 28° Congresso Annuale della American Society of Gene and Cell Therapy (ASGCT).
L'evento si svolgerà dal 13 al 17 maggio a New Orleans, LA, con opzioni di partecipazione sia in presenza che virtuale. L'azienda presenterà un poster intitolato "CD45 come bersaglio universale per la terapia adiuvante con cellule TCR-T dopo trapianto allogenico di cellule ematopoietiche."
- Data della presentazione: martedì 13 maggio
- Orario: 18:00 - 19:30 ora centrale
- Luogo: Poster Hall, Sala I2
- Numero abstract: AMA1180
Il materiale della presentazione sarà disponibile sul sito web di TScan (tscan.com) nella sezione "Pubblicazioni" dopo la conclusione dell'evento.
TScan Therapeutics (Nasdaq: TCRX), una empresa biotecnológica en etapa clínica que desarrolla terapias con células T modificadas con TCR para el tratamiento del cáncer, ha anunciado su próxima presentación en la 28ª Reunión Anual de la American Society of Gene and Cell Therapy (ASGCT).
El evento se llevará a cabo del 13 al 17 de mayo en Nueva Orleans, LA, con opciones de asistencia presencial y virtual. La empresa presentará un póster titulado "CD45 como objetivo universal para la terapia adyuvante con células TCR-T tras el trasplante alogénico de células hematopoyéticas."
- Fecha de presentación: martes 13 de mayo
- Hora: 6:00 - 7:30 p.m. hora central
- Ubicación: Poster Hall, Sala I2
- Número de resumen: AMA1180
Los materiales de la presentación estarán disponibles en el sitio web de TScan (tscan.com) en la sección "Publicaciones" después de que finalice la presentación.
TScan Therapeutics (나스닥: TCRX)는 암 치료를 위한 TCR 공학 T세포 치료제를 개발하는 임상 단계의 바이오테크 회사로, 미국 유전자 및 세포 치료 학회(ASGCT) 제28회 연례 회의에서 곧 발표할 예정임을 발표했습니다.
행사는 5월 13일부터 17일까지 루이지애나주 뉴올리언스에서 대면 및 온라인 참석 옵션으로 진행됩니다. 회사는 "동종 조혈모세포 이식 후 보조 TCR-T 세포 치료를 위한 보편적 표적 CD45"라는 주제의 포스터를 발표할 예정입니다.
- 발표 일시: 5월 13일 화요일
- 시간: 오후 6시 - 7시 30분 (중부 표준시)
- 장소: 포스터 홀, 홀 I2
- 초록 번호: AMA1180
발표 자료는 발표 종료 후 TScan 웹사이트(tscan.com)의 "출판물" 섹션에서 제공될 예정입니다.
TScan Therapeutics (Nasdaq : TCRX), une entreprise biotechnologique en phase clinique développant des thérapies cellulaires TCR-ingénierisées pour le traitement du cancer, a annoncé sa prochaine présentation lors de la 28e réunion annuelle de l'American Society of Gene and Cell Therapy (ASGCT).
L'événement se déroulera du 13 au 17 mai à La Nouvelle-Orléans, Louisiane, avec des options de participation en personne et virtuelle. L'entreprise présentera un poster intitulé "CD45 comme cible universelle pour la thérapie adjuvante par cellules TCR-T après une transplantation allogénique de cellules hématopoïétiques."
- Date de présentation : mardi 13 mai
- Heure : 18h00 - 19h30 heure centrale
- Lieu : Hall des posters, Hall I2
- Numéro de résumé : AMA1180
Les documents de présentation seront disponibles sur le site web de TScan (tscan.com) dans la section "Publications" après la fin de la présentation.
TScan Therapeutics (Nasdaq: TCRX), ein biotechnologisches Unternehmen in der klinischen Phase, das TCR-modifizierte T-Zell-Therapien zur Krebsbehandlung entwickelt, hat seine bevorstehende Präsentation auf der 28. Jahrestagung der American Society of Gene and Cell Therapy (ASGCT) angekündigt.
Die Veranstaltung findet vom 13. bis 17. Mai in New Orleans, LA, statt und bietet sowohl persönliche als auch virtuelle Teilnahmeoptionen. Das Unternehmen wird ein Poster mit dem Titel "CD45 als universelles Ziel für adjuvante TCR-T-Zelltherapie nach allogenem hämatopoetischem Zelltransplantat" präsentieren.
- Präsentationsdatum: Dienstag, 13. Mai
- Uhrzeit: 18:00 - 19:30 Uhr Central Time
- Ort: Posterhalle, Halle I2
- Abstract-Nummer: AMA1180
Die Präsentationsmaterialien werden nach Abschluss der Präsentation auf der Website von TScan (tscan.com) im Bereich "Publikationen" verfügbar sein.
- Acceptance of research abstract for presentation at major industry conference (ASGCT) showcasing CD45 as potential universal target for TCR-T cell therapy
- Research presentation indicates progress in company's TCR-T therapy development pipeline
- None.
WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of an abstract for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28ᵗʰ Annual Meeting being held May 13 – 17 in New Orleans, LA as well as virtually.
Poster Presentation Details:
Title: CD45 as a Universal Target for Adjuvant TCR-T Cell Therapy Following Allogeneic Hematopoietic Cell Transplantation
Authors: Kostadin O Petrov, Stephen P Carroll, Kenneth L Jahan, Rakshi Bala, Vivin Karthik, Debanjan Goswamy, Hannah Bader, Alok Das Mahopatra, Daniel C Pollacksmith, Shubhangi Kamalia, Nivya Sharma, Victor Ospina, Sanket Revadkar, Drashti Shah, Ryan E Kritzer, Hana Husic, Shobitha Jillella, Nicole Ladd, Shoshana Bloom, Rachel Lent, Prachi Dhanania, Chandan K Pavuluri, Carolyn Hardy, Alexander Cristofaro, Zhonghua Zhu, Livio Dukaj, Kimberly M Cirelli, Antoine Boudot, Mollie M Jurewicz, Cagan Gurer
Abstract Number: AMA1180
Session Date/Time: Tuesday, May 13; 6:00 - 7:30 p.m. Central Time
Location: Poster Hall, Hall I2
A copy of the presentation materials will be added to the “Publications” section of the Company’s website at tscan.com once the presentation has concluded.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA™ Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers (the PLEXI-T™ Phase 1 solid tumor trial). The Company is currently enrolling patients into both clinical programs.
Contacts
Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com
Maghan Meyers
Argot Partners
212-600-1902
TScan@argotpartners.com
FAQ
When will TScan Therapeutics (TCRX) present at ASGCT 2025?
What is TScan Therapeutics (TCRX) presenting at ASGCT 2025?
Where can investors find TScan (TCRX) ASGCT presentation materials?
What type of therapy is TScan Therapeutics (TCRX) developing?
Is the ASGCT 2025 conference where TScan (TCRX) is presenting available virtually?
